SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer


SPARC/osteonectin expression is reportedly altered in various malignancies. However, little is known regarding to the prognostic value of SPARC in triple-negative breast cancer (TNBC) patients. In this study, immunohistochemistry and immunoreactive scores (IRSs) were used to evaluate SPARC protein expression in primary tumors from 211 TNBC patients with up… (More)
DOI: 10.18632/oncotarget.10532


4 Figures and Tables